Pricing Log in Create free account
Friday 6 November 2026 Export LNTH’s income statement to Excel — free account

Lantheus Holdings, Inc.

LNTH Healthcare Drug Manufacturers Specialty & Generic

Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024.

Revenue
+1.54%
EPS
−17.1%
Free cash flow
+7.71%
Total debt
+0.52%

Quarter to September 2026, against a year earlier

100.76 0.38 −0.38%
Market cap
$6.6B
P/E
24.3×
Fwd P/E
21.3×
Dividend yield
—
F-score
5/9
Altman Z
4.25
Beneish M
−2.23
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Lantheus Holdings, Inc. (LNTH) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, Lantheus Holdings, Inc. (LNTH) trades at a EV/EBITDA of 16.7×. Over the past ten years it has ranged from 0.0× (March 2022) to 329× (May 2023); the current reading is higher than 71% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 12.2× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 12.2× 9.79%
FY2024 11.1× 14.69%
FY2023 9.7× (77.10%)
FY2022 42.3× —
FY2021 0.0× —
FY2020 42.2× 209.03%
FY2019 13.6× 44.72%
FY2018 9.4× (29.92%)
FY2017 13.5× 101.48%
FY2016 6.7× 6.26%

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 16.5× (9.32%)
Jun 2026 18.2× 36.75%
Mar 2026 13.3× 9.28%
Dec 2025 12.2× 39.78%
43 more quarters

Against its own ten years

Low 0.0× High 329×
Ten-year median 12.3×
Current reading's percentile 71

EV/EBITDA against peers

Company EV/EBITDA
HIMS Hims & Hers Health, Inc. compare n/m
AMLX Amylyx Pharmaceuticals, Inc. compare n/m
SUPN Indivior Pharmaceuticals Inc. compare 7.0×
AMRX AMNEAL PHARMACEUTICALS, INC. compare 14.3×
LNTH Lantheus Holdings, Inc. 16.7×
LQDA Liquidia Corporation compare 22.7×
RDY Dr. Reddy's Laboratories Ltd compare 22.9×
ALKS Alkermes plc compare 37.9×
KNSA Kiniksa Pharmaceuticals International, plc compare 48.0×
Drug Manufacturers Specialty & Generic industry median 12.2×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on LNTH